Neurocrine Biosciences (NBIX) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $3.29
- Estimate
- $2.75
- Surprise
- +19.8%
- Revenue (period 2026-09-30)
- $1.12B
- Score today
- 7.3/10
Revenue source: xbrl.
How the report landed
Neurocrine Biosciences (NBIX) beat the $2.75 estimate with adjusted EPS of $3.29 — a large 19.8% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates NBIX Buy (Wait) at 7.3/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's +19.8% surprise compares with a +15.4% four-quarter average.
What supports the rating
- V7 flight-to-quality bonus: +0.5 (Q=8.3 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Concentration risk — Product: INGREZZA
- Overbought (RSI 78)
- Below 200-day MA
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $145.35
- Entry target
- $142.53
- Price target
- $185.60
- Stop
- $136.21
- Upside to target
- +27.7%
- Reward-to-risk
- 3.1:1
The stock trades at 21.6× trailing but 12.1× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: RSI 78 — a level conventionally read as overbought; gains at these levels often lean on momentum; trading volume is running 1.6× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-11-03 — shown for context, not personalized investment advice.
NBIX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $14.77B
- P/E (fwd)
- 12.1
- P/E (ttm)
- 21.6
- 52-week range
- $122.14–$186.12
- Off 52-week high
- 21.9%
- RSI (14)
- 78
- Volume vs avg
- 1.64×
- Score today
- 7.3/10